

## Prof. Evelina Tacconelli, MD, Phd

Email :[evelina.tacconelli@med.uni-tuebingen.de](mailto:evelina.tacconelli@med.uni-tuebingen.de)

Date of birth: 26.11.1967



**1) Current position:** Full Professor of Infectious Diseases, University of Verona, Italy; Medical director of the Comprehensive Center of Infectious Diseases, Tübingen University, Germany

**2) University education with degree:** Medical University (09/1986 – 07/1992), Infectious Diseases Specialization (09/1992 – 07/1996), Catholic University, Rome, Italy; Master in epidemiology for Public Health operators (09/1997 – 07/1998), La Sapienza University, Rome, Italy

**3) Scientific degrees:** Dott. in Medicine and Surgery, Catholic University, Rome, Italy, 1992; Specialization in Infectious Diseases, Catholic University, Rome, Italy, 1996

### 4) Professional career since final degree

Since Oct 2017	Full Professor, Infectious Diseases, University of Verona, Italy
Since 2013	Full Professor, Infectious Diseases, University of Tübingen; Medical Director Comprehensive Center for infectious Diseases, University Hospital Tübingen
2013-2017	Head of Infectious Diseases Division, Internal Medicine I, University hospital, Tübingen
2003-2007	Lecturer on Medicine, Infectious Diseases, BIDMC and Harvard Medical School, Boston, USA
1999 – 2013	Assistant Professor, Infectious Diseases, Catholic University, Rome, Italy
1997-1999	Infectious Diseases Specialist, Catholic University, Rome, Italy

### 5) Academic management positions:

Since 2009	Education Officer of Infectious Diseases and Clinical Microbiology for the European Society of Clinical Microbiology and Infectious Disease (ESCMID)
Since 2015	Chair of EUCIC (European Committee of infection Control)
Since 2017	ESCMID Group for the guidelines for the therapy of multidrug-resistant gram-negative bacteria, Chairman
Since 2016	ESCMID Group for the guidelines for the decolonisation of multidrug-resistant gram-negative bacteria, Chairman
2010 – 2013	ESCMID Group for guidelines for the control of hospital spreading of multidrug-resistant gram-negative bacteria, Chairman
2012 – 2013	External Affairs Committee of SHEA
Since 2009	ECDC Consultant for antibiotic stewardship and MDR-gram negative bacteria
Since 2010	WHO Consultant on antimicrobial resistance and infection control
2008-2012	ISC risk assessment of MRSA group (International Society of Chemotherapy Working Group on MRSA), Chairman
2009-2013	Study Group on Antibiotic Resistance in Hospitalised Patients of SIMIT (Italian Society of Infectious Diseases), Chairman

Since 2009	Executive Committee of GISIT (Italian Study Group of Infectious Diseases)
2012-2013	ESCMID Study Group on Infections in the Elderly (ESGIE), Chairman
2014-2017	Chair of the Antibiotics Committee, UKET, Tübingen, Chairman
Since 2014	Clinical Advisory Board for HZI (Helmholtz Zentrum für Infektionsforschung)
2014-2016	Advisory Board for DGI (Deutsche Gesellschaft für Infektiologie)
Since 2012	International Advisory Board for Lancet Infectious Diseases
Since 2009	Editorial Board for Journal of Antimicrobial Chemotherapy

**7) Areas of scientific interest:** Epidemiology and clinical aspects of health-care associated infections; antimicrobial stewardship; Infection control and public health

**8) Author and co-author of 180 papers listed in SCI-JCR, and NIH Medline (6849 citations, 47 H-index). Ten selected publications:**

1. Tacconelli E, et al. Surveillance for control of antimicrobial resistance. *Lancet Infect Dis.* Oct 2017, 1-8 **(IF 19.9)**
2. Gladstone BP,.. Tacconelli E. Antimicrobial resistance rates in gram-positive bacteria do not drive glycopeptides use. *PLoS One.* 2017 Jul 20;12(7):e0181358. **(IF 3.5)**
3. Tacconelli E, et al. Discovery, research and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria. *Lancet Infect Dis.* 2017 **(IF 19.9)**
4. Baur D, ... Tacconelli E. Effect of antibiotic stewardship on the incidence of infection and colonization with antibiotic-resistant bacteria and *Clostridium difficile* infection: a systematic review and meta-analysis. *Lancet Infect Dis.* 2017 Sep;17(9):990-1001. **(IF 19.9)**
5. Tacconelli E, et al. ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. *Clin Microbiol Infect.* 2014 Jan;20 Suppl 1:1-55. **(IF 5.1)**
6. Tacconelli E, et al. Rapid screening tests for methicillin-resistant *Staphylococcus aureus* at hospital admission: systematic review and meta-analysis. *Lancet Infect Dis.* 2009 Sep;9(9):546-54. **(IF 19.9)**
7. Tacconelli E, et al. Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study. *Antimicrob Agents Chemother.* 2009 Oct;53(10):4264-9. **(IF 4.6)**
8. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. *Curr Opin Infect Dis.* 2009 Aug;22(4):352-8. **(IF 4.2)**
9. Tacconelli E, et al. Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant *Acinetobacter baumannii calcoaceticus* complex. *J Antimicrob Chemother.* 2008 Nov;62(5):1130-7. **(IF 5)**
10. Tacconelli E, et al. Preventing the influx of vancomycin-resistant enterococci into health care institutions, by use of a simple validated prediction rule. *Clin Infect Dis.* 2004 Oct 1;39(7):964-70. **(IF 8.8)**

**9) Books:**

- E. Tacconelli, Risk assessment for MRSA in: Gould. Antibiotic policies: fighting resistance, Springer US, 2007 and 2010;
- E. Tacconelli, U. Frank, The Daschner Guide to in-hospital antibiotic therapy, Springer 1-250 1<sup>st</sup> ed. 2009, 2<sup>nd</sup> ed. 2011;
- E. Tacconelli, F. Foschi, M. Pletz, Antibiotic usage and surgical prophylaxis, in Cohen, Principles of Infectious Diseases, Springer 7<sup>th</sup> ed 2015



June, 20, 2018

"Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".